All News
Shared decision making is a key!! @RheumNow #Rnl2022
Data shows more compliance !! which is a key in managing chronic illnesses. https://t.co/ZuJMd4Bd9c
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Do you use shared decision making in your clinic? #RNL2022 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow #RNL2022 https://t.co/wCb0mPBMjA
Dr. Rachel Tate uptoTate ( View Tweet)
Have you heard the term "Pharmionics?" It's the study about how ambulatory patients use and misuse prescription drugs. In most clinics, DMARD adherence is around 50% or less. Dr. Kaleb Michaud #RNL2022 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Let's start with difficult to treat RA
Seronegative RA should be an opportunity to reconsider the diagnosis🤔
@RheumNow #RNL2022 https://t.co/EZhrk0b40E
Robert B Chao, MD doctorRBC ( View Tweet)
For RA patients who've failed multiple DMARDs and biologics, it may be time to "Ctrl-Alt-Del" reset and consider
1) what tx pt failed?
2) what will the pt NOT take
3) did any tx help?
@RheumNow #RNL2022 https://t.co/VhXkN9j9IO
Robert B Chao, MD doctorRBC ( View Tweet)
Some RA phenotypes, One day will have OA phenotypes.
@RheumNow #Rnl2022 https://t.co/rVb6cfqSTZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Comprehensive table on what therapies to avoid based on co-morbidities.
Excellent talk by Dr. Cush!
@RheumNow #RNL2022 https://t.co/GaTH3ftfjT
Robert B Chao, MD doctorRBC ( View Tweet)
Whats your MTX day or whats your injection date ?! always help to know how adherent your patient is to once weekly medications ?!
@RheumNow #Rnl2022 Great talk by @Dr_K https://t.co/b7R1NpgeTc
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Can we predict which patient respond to which treatment?! Seropositivity? True for Rituximab and Abatacept! what about seronegative ?
@RheumNow #Rnl2022 Amazing talk by Ernest choy. https://t.co/NHosJrQ8yG
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Heterogeneous pathology leads to heterogeneous response to treatment!
Synovium plasma gene expression🤓
Precision and rheumatology!
Ernest Choy @RheumNow #Rn12022 https://t.co/E2j2oD3RaA
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Precision medicine in RA. Synovial biopsy and synovial molecular signature can predict radiographic progression
@RheumNow #RNL2022 https://t.co/7WPGVhRMD5
Robert B Chao, MD doctorRBC ( View Tweet)
Not bacteria it self, the metabolic changes ( heat map) predict response to treatment! Very interesting 🤓.
NSAIDS change the microbiota😲, didn't see that coming !
@RheumNow Ernest Chiy #Rnl2022 https://t.co/QQoubmVRsn
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Ernest Choy on how gut microbiome can affect RA prognosis and treatment
Our gut microbiota can be changed by diet and medications (NSAIDs)
@RheumNow #RNL2022 https://t.co/Cp19kG3z8D
Robert B Chao, MD doctorRBC ( View Tweet)
3 different Pathotypes at level of synovium and treatment decision!
Sunovium signature, identify signature for response to treatment
▶️ CXCL13 IL 6
▶️ ICAM TNF
@RheumNow Ernest Choy #Rnl2022 https://t.co/252fYM1PnY
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Is it really seronegative RA!!!!
Happening now. #RnI2022 @RheumNow https://t.co/R3UTYuZRvJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
“best laid plans of mice and men oft go astray”.
Dr. Cush giving his opening remarks and pod at #Rnl2022 https://t.co/o9lenN1Dkd
Dr. John Cush RheumNow ( View Tweet)
Welcome to #RNL2022 !
Not only are we in-person in Texas, we have people online from all over the US and Canada to New Zealand and Japan!
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is kicking off with a pod on Rheumatoid Arthritis - Future Improvements. Dr. Cush will lead the first presentation on Treatment Choices in Refractory RA. #RNL2022 https://t.co/H3RbDPZxM1
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is HERE. Welcome everyone! What pod are you looking forward to the most?
Anyone out there who is still on the fence--virtual registration is still open. Join us!
https://t.co/3wKgCKqvfD
#RNL2022 https://t.co/W2hUpZ2Y8N
Links:
Dr. John Cush RheumNow ( View Tweet)